These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 28208086)

  • 21. Spectrum of Autoimmune Bullous Diseases in Northern Greece. A 4-year Retrospective Study and Review of the Literature.
    Patsatsi A; Lamprou F; Kokolios M; Stylianidou D; Trigoni A; Kalampalikis D; Sotiriadis D
    Acta Dermatovenerol Croat; 2017 Oct; 25(3):195-201. PubMed ID: 29252171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Skin-Related Quality of Life During Autoimmune Bullous Disease Course.
    Hopkins ZH; Jimenez A; Taliercio VL; Clarke JT; Hansen CB; Hull CM; Rhoads JLW; Zone JJ; Sahni VN; Kean J; Secrest AM
    JAMA Dermatol; 2023 Nov; 159(11):1185-1194. PubMed ID: 37703003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany.
    Bertram F; Bröcker EB; Zillikens D; Schmidt E
    J Dtsch Dermatol Ges; 2009 May; 7(5):434-40. PubMed ID: 19170813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enzyme-linked immunosorbent assay in autoimmune blistering diseases: preliminary experience of the Dermatology Department of Cagliari.
    Atzori L; Deidda S; Aste N
    G Ital Dermatol Venereol; 2008 Feb; 143(1):1-8. PubMed ID: 18833046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Nomacopan for Treatment of Bullous Pemphigoid: A Phase 2a Nonrandomized Controlled Trial.
    Sadik CD; Rashid H; Hammers CM; Diercks GFH; Weidinger A; Beissert S; Schauer F; Fettiplace J; Thaçi D; Ngai Y; Nunn MA; Zillikens D; Horváth B
    JAMA Dermatol; 2022 Jun; 158(6):641-649. PubMed ID: 35507334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics and quality of life in pemphigus patients.
    Tee CT; Lee CS; Gunabalasingam P
    Med J Malaysia; 2022 May; 77(3):324-330. PubMed ID: 35638489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Animal models to investigate pathomechanisms and evaluate novel treatments for autoimmune bullous dermatoses.
    Iwata H; Bieber K; Hirose M; Ludwig RJ
    Curr Pharm Des; 2015; 21(18):2422-39. PubMed ID: 25777758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autoimmune bullous diseases in Austria.
    Laimer M; Pohla-Gubo G; Kraus L; Nischler E; Bauer JW; Ahlgrimm-Siess V; Hintner H
    Dermatol Clin; 2011 Oct; 29(4):691-8. PubMed ID: 21925021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validity and reliability of the Polish version of myasthenia gravis - Quality of life questionnaire - 15 item.
    Rozmilowska I; Adamczyk-Sowa M; Pierzchala K; Czyzewski D
    Neurol Neurochir Pol; 2017; 51(4):311-318. PubMed ID: 28579082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spectrum of autoimmune bullous diseases among children in Kuwait.
    Nanda A; Lazarevic V; Rajy JM; Almasry IM; AlSabah H; AlLafi A
    Pediatr Dermatol; 2021 Jan; 38(1):50-57. PubMed ID: 33043506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spectrum of Autoimmune Bullous Diseases in the Middle East: A 15-Year Review.
    Haber R; Helou J; Habr C; Tomb R
    Skinmed; 2017; 15(3):181-186. PubMed ID: 28705277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Objective scoring systems for disease activity in autoimmune bullous disease.
    Sebaratnam DF; Murrell DF
    Dermatol Clin; 2011 Jul; 29(3):515-20, xi. PubMed ID: 21605820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical, demographic and immunopathological spectrum of subepidermal autoimmune bullous diseases at a tertiary center: A 1-year audit.
    De D; Khullar G; Handa S; Saikia UN; Radotra BD; Saikia B; Minz RW
    Indian J Dermatol Venereol Leprol; 2016; 82(3):358. PubMed ID: 27088957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sexual quality of life in patients with pemphigus: A case-control study.
    Maione V; Bettolini L; Cozzi C; Bighetti S; Tomasi C; Calzavara-Pinton P
    J Eur Acad Dermatol Venereol; 2024 Apr; 38(4):761-768. PubMed ID: 38071729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Role of Mast Cells in Autoimmune Bullous Dermatoses.
    Yu X; Kasprick A; Hartmann K; Petersen F
    Front Immunol; 2018; 9():386. PubMed ID: 29541076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of autoimmune bullous diseases in France: a nationwide network of 30 centers.
    Meyer N; Paul C; Joly P
    Dermatol Clin; 2011 Oct; 29(4):659-62. PubMed ID: 21925014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence of pemphigoid diseases in Northern Germany in 2016 - first data from the Schleswig-Holstein Registry of Autoimmune Bullous Diseases.
    van Beek N; Weidinger A; Schneider SW; Kleinheinz A; Gläser R; Holtsche MM; von Georg A; Hammers CM; Hübner F; Lima AL; Gola D; Sadik CD; Zillikens D; Katalinic A; Schmidt E; König IR
    J Eur Acad Dermatol Venereol; 2021 May; 35(5):1197-1202. PubMed ID: 33428263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retrospective Study on Autoimmune Blistering Disease in Paediatric Patients.
    Kong YL; Lim YL; Chandran NS
    Pediatr Dermatol; 2015; 32(6):845-52. PubMed ID: 26391853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Polish version of the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) - four-stage translation and validation.
    Karbownik-Lewińska M; Lewiński A; McKenna S; Kokoszko A; Mucha S; Komorowski J; Krzyzanowska-Swiniarska B; Gryczyńska M; Sowiński J; Junik R; Meads D; Kołtowska-Häggström M
    Endokrynol Pol; 2008; 59(5):374-84. PubMed ID: 18979446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vitamin D status in patients with autoimmune bullous dermatoses: a meta-analysis.
    Yang M; Wu H; Zhao M; Long H; Lu Q
    J Dermatolog Treat; 2022 May; 33(3):1356-1367. PubMed ID: 32799714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.